Ernest Mario Overview

  • Investor Type
  • Angel
  • Investments
  • 2
  • Portfolio
  • 1
  • Exits
  • 1
Exits

Ernest Mario General Information

Description

Dr. Ernest Mario serves as Advisory Board Executive at Metalmark Capital. Dr. Mario served as Board Member at Balance Therapeutics & Tonix Pharmaceuticals Holding. He also serves as Advisor at Tectonic Ventures. He also serves as Venture partner at Pappas Ventures. Ernie's career began in 1966 as a pharmaceutical researcher at Strasenburgh Laboratories in Rochester, NY. He later held various management positions within SmithKline and Squibb Corp., overseeing operations, quality control, and manufacturing. He was elected to the Squibb Board in 1984. He joined Glaxo plc in 1986 and subsequently served as Chief Executive and Deputy Chairman, during which time he oversaw the launch of five major brands that grew the company's sales and profits by nearly 15 percent annually, as Glaxo became the second largest global pharmaceutical company. In 1993, Ernie joined Alza Corporation as CEO, where he ultimately consummated with Johnson & Johnson one of the largest mergers in pharmaceutical history. In 2001, Ernie founded Apothogen, a company involved in early stage pharmaceutical development, which subsequently merged with IntraBiotics. He recently retired from Reliant Pharmaceuticals where he served as CEO and Chairman of the Board of Directors since 2003. Ernie currently is Chairman of Pappas Ventures' portfolio company Chimerix (Nasdaq: CMRX). An adjunct professor of pharmacy at the University of Rhode Island, Ernie also holds honorary doctorates from the University of Rhode Island and Rutgers University where the School of Pharmacy bears his name. In addition to his service on the boards of several publicly traded corporations, Ernie is active with numerous educational and healthcare organizations, including the American Foundation of Pharmaceutical Education (AFPE), for which he serves as chairman. In 2007, he was awarded the Remington Medal, the highest honor in the field of Pharmacy in the United States. He also served as the Board Member at Boston Scientific. He also serves as Board Member at Fervent Pharmaceuticals. Dr. Ernest Mario serves as the Chairman of the Board of Directors at Nurigene. He is the Chairman of the board at Orbus Therapeutics. He previously served as a Chairman of Capnia and Chimerix.

Contact Information

Primary Investor Type
Angel (individual)
Primary Office
  • 1177 Avenue of the Americas
  • 40th Floor
  • New York, NY 10036
  • United States
+1 (212) 000-0000

Ernest Mario Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Orbus Therapeutics 19-Aug-2015 Early Stage VC 000.00 Drug Discovery Generating Revenue
0000000000 0000000 18-Jan-2012 00000 (00000 00.000 Other Devices and Supplies Out of Business
To view Ernest Mario’s complete investments history, request access »
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ernest Mario Exits (1)

Company Name Exit Date Exit Type Exit Size
0000000000 0000000 01-Apr-2013 0000000000: 000000
To view Ernest Mario’s complete exits history, request access »

Ernest Mario Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Ernest Mario Team (1)

Name Title Deals Funds Boards Office
Ernest Mario Ph.D Angel Investor 0 0 0 New York, NY
To view Ernest Mario’s complete team members history, request access »